ANGO

Over the past six months, AngioDynamics' stock has been influenced by several key events. In October 2026, the Q1 Fiscal Year 2027 earnings report showed results exceeding analyst expectations for adjusted loss per share and revenue, with net sales increasing by 6.9% year-over-year, driven by 13.2% growth in the Med Tech segment. Despite beating estimates, the stock declined approximately 21% in a single session and 24.8% over 30 days, as investors focused on the company's continued losses. Also in October 2026, the company announced Eric Honroth as the new President and CEO, succeeding Jim Clemmer, which contributed to near-term stock uncertainty. Additionally, AngioDynamics received FDA Investigational Device Exemption (IDE) approval in October 2026 to begin the RELIEF feasibility study for its NanoKnife IRE platform in treating benign prostatic hyperplasia (BPH). In July 2026, the company reported record fiscal fourth-quarter and full-year results for fiscal year 2026, with net sales rising 9.5% to $320.2 million and Med Tech segment sales growing 18.4% year-over-year, leading to an advance in the stock price due to these results and NanoKnife catalysts, including new CPT codes and Medicare reimbursement. The company also participated in investor conferences, including Canaccord Genuity's 46th Annual Growth Conference in August 2026 and the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026.